Advertisement

Topics

Swedish Orphan Biovitrum AB: Elocta Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU

10:27 EDT 23 Sep 2016 | FinanzNachrichten

Swedish Orphan Biovitrum AB (publ) (Sobi™) (http://www.sobi.com/) (STO:SOBI) today announces that the company's product Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion prote...

Original Article: Swedish Orphan Biovitrum AB: Elocta Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU

NEXT ARTICLE

More From BioPortfolio on "Swedish Orphan Biovitrum AB: Elocta Obtains National Reimbursement in Spain, Now Available in the Five Largest Markets in the EU"

Quick Search
Advertisement
 

Relevant Topic

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...